The API2-ALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling

Oncogene

Volumn 33, Issue 19, 2014, Pages 2520-2530

  Rosebeck, S ^a,f   Rehman, A O ^a   Apel, I J ^a   Kohrt, D ^a,g   Appert, A ^b   O'Donnell, M A ^c   Ting, A T ^c   Du, M Q ^b   Baens, M ^d,e   Lucas, P C ^a,h   McAllister Lucas, L M ^a,h  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f UNIVERSITY OF CHICAGO   (United States)

^g The Holleran Center for Community Action and Public Policy   (United States)

^h CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

lymphoma; MALT1; RIP1; TRAF2; ubiquitination

Indexed keywords

API2 MALT1 FUSION PROTEIN; BINDING PROTEIN; HYBRID PROTEIN; LYSINE; ONCOPROTEIN; PROTEIN RIP1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; AGFG1 PROTEIN, HUMAN; API2 MALT1 FUSION PROTEIN, HUMAN; API2-MALT1 FUSION PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOPORIN; RNA BINDING PROTEIN;

ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMAGENESIS; MARGINAL ZONE LYMPHOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SOLID TUMOR; UBIQUITINATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; LYMPHOMA, B-CELL, MARGINAL ZONE; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION; ONCOGENES; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TRANSFECTION; UBIQUITINATION;

EID: 84900440433     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.195     Document Type: Article

References (53)

1. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4: 644-653.
2. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601-3609.
3. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785-5794.
4. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999; 59: 6205-6213.
5. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
6. Liu H, Ye H, Dogan A, Ranaldi R, Hamoudi RA, Bearzi I et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98: 1182-1187.
7. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.
8. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22: 63-68.
9. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335-2339.
10. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006; 210: 171-186.
11. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000; 6: 961-967.
12. Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 2001; 276: 19012-19019.
13. Thome M, Charton JE, Pelzer C, Hailfinger S. Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2010; 2: a003004.
14. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004; 427: 167-171.
15. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14: 289-301.
16. Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 2007; 26: 4634-4645.
17. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011; 331: 468-472.
18. Zhou H, Du MQ, Dixit VM. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005; 7: 425-431.
19. Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 2007; 26: 5643-5654.
20. Garrison JB, Samuel T, Reed JC. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 2009; 28: 1584-1593.
21. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78: 681-692.
22. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.
23. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387-396.
24. Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem 2009; 284: 35906-35915.
25. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
26. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
27. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY et al. Sphingo-sine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010; 465: 1084-1088.
28. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22: 245-257.
29. Li H, Kobayashi M, Blonska M, You Y, Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem 2006; 281: 13636-13643.
30. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006; 8: 398-406.
31. Conze DB, Zhao Y, Ashwell JD. Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol 2010; 8: e1000518.
32. Lee TH, Shank J, Cusson N, Kelliher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 2004; 279: 33185-33191.
33. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
34. O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol 2007; 17: 418-424.
35. Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 2006; 66: 5270-5277.
36. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011; 471: 591-596.
37. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68: 9384-9393.
38. Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA 2004; 101: 9079-9084.
39. Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P et al. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions. J Biol Chem 2007; 282: 10180-10189.
40. Duprez L, Bertrand MJ, Vanden Berghe T, Dondelinger Y, Festjens N, Vandena-beele P. Intermediate domain of receptor-interacting protein kinase 1 (RIPK1) determines switch between necroptosis and RIPK1 kinase-dependent apoptosis. J Biol Chem 2012; 287: 14863-14872.
41. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol 2003; 326: 105-115.
42. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-548.
43. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov 2012; 2: 140-155.
44. Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S et al. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 2011; 31: 2774-2786.
45. Yin Q, Lamothe B, Darnay BG, Wu H. Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry 2009; 48: 10558-10567.
46. Cardamone MD, Krones A, Tanasa B, Taylor H, Ricci L, Ohgi KA et al. A protective strategy against hyperinflammatory responses requiring the nontranscriptional actions of GPS2. Mol Cell 2012; 46: 91-104.
47. Peng C, Zhu F, Wen W, Yao K, Li S, Zykova T et al. TRAF2 is a key mediator of the EGF-induced RSK2/CREB/Fos signaling pathway. J Biol Chem 2012; 287: 25881-25892.
48. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327: 1135-1139.
49. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008; 9: 263-271.
50. Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011; 30: 1742-1752.
51. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J 1996; 15: 6189-6196.
52. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nunez G et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J 2008; 27: 373-383.
53. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 2011; 145: 92-103.